Imepitoin

Imepitoin
Clinical data
Trade names	Pexion
Other names	AWD 131-138; ELB-138
Routes of; administration	Oral
ATCvet code	QN03AX90 (WHO) ;
Identifiers
	IUPAC name 3-(4-Chlorophenyl)-5-morpholin-4-yl-4H-imidazol-2-one;
CAS Number	188116-07-6;
PubChem CID	3083511;
ChemSpider	2340703;
UNII	19V39682LI;
ChEMBL	ChEMBL204240;
CompTox Dashboard (EPA)	DTXSID50172160 ;
ECHA InfoCard	100.220.751
Chemical and physical data
Formula	C13H14ClN3O2
Molar mass	279.72 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl;
	InChI InChI=1S/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4H,5-9H2; Key:IQHYCZKIFIHTAI-UHFFFAOYSA-N;

Imepitoin (INNTooltip International Nonproprietary Name), sold under the brand name Pexion, is an anticonvulsant which is used in veterinary medicine in Europe to treat epilepsy in dogs.^[1]^[2]^[3]^[4] It was recently^[when?] approved in the United States.^[2]^[3]^[4] The drug also has anxiolytic effects.^[1]^[2] It was originally developed to treat epilepsy in humans, but clinical trials were terminated upon findings of unfavorable metabolic differences in smokers and non-smokers.^[1]^[2]

Quick Facts Clinical data, Trade names ...

Close

Imepitoin acts as a low-affinity (4,350–5,140 nM; relative to K_i = 6.8 nM for diazepam and K_i = 1.7 nM for clonazepam) partial agonist of the benzodiazepine site of the GABA_A receptor (up to 12–21% of the maximal potentiation of diazepam, a full agonist of this site).^[1] It is the first partial agonist to be approved for the treatment of epilepsy.^[1] The drug also dose-dependently blocks voltage-gated calcium channels.^[3] It is not a benzodiazepine; instead, it is an imidazolone, and bears some structural similarities to hydantoin anticonvulsants like ethotoin and phenytoin.^[1]

See also